BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 29, 2026
Breaking News: Science fiction realized: BCI tech is hereBreaking News: FDA says yes to Viridian’s Lumvoa in TEDBreaking News: Science fiction realized: BCI tech is here
Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
BioWorld Science, Cancer RSS Feed RSS

Cancer

Combined targeting of NOX2 and FLT3 improves AML treatment efficacy

April 14, 2023
Mutations in fms-related receptor tyrosine kinase 3 (FLT3) are related to the increase of reactive oxygen species (ROS) in acute myeloid leukemia (AML). Recent studies suggest that by regulating ROS production and antioxidant expression, oncogenes such as FLT3 directly influence leukemia progression, even during anticancer therapy.
Read More
Cancer

NR2F2 isoform pushes melanoma into metastatic form

April 14, 2023
It is known that in melanoma, transformed melanocytic cells acquire stem cell-like features; these cells have multilineage differentiation potential, thus allowing them to morph into cell states with neural crest cell (NCC)-like, epithelial-to-mesenchymal transition-like features, promoting its metastatic potential.
Read More
CAR T cell attacking cancer cells
Cancer

WARF and Ginkgo Bioworks partner to discover next-generation GD2 CAR T-cell therapies

April 14, 2023
The Wisconsin Alumni Research Foundation (WARF) and Ginkgo Bioworks Inc. have announced a partnership to leverage Ginkgo's proprietary high-throughput combinatorial chimeric antigen receptor (CAR) discovery and screening platform with the aim of discovering next-generation GD2 CAR T-cell therapies.
Read More
Immuno-oncology

Pyramid Biosciences and Genequantum Healthcare enter license agreement for ADC targeting TROP2

April 14, 2023
Pyramid Biosciences Inc. and Genequantum Healthcare (Suzhou) Co. Ltd. have entered into an exclusive license agreement to develop and commercialize GQ-1010, a potential best-in-class antibody-drug conjugate (ADC) targeting trophoblast cell surface antigen 2 (TROP2), worldwide except for Greater China (mainland China, Hong Kong, Macau, and Taiwan).
Read More
Microscope with laptop displaying histology image.
Cancer

SJ-1461, a novel potent and orally bioavailable BET inhibitor

April 14, 2023
Researchers from University of Belgrade, St. Jude Children’s Research Hospital and affiliated organizations have provided details on the discovery of novel orally bioavailable BET inhibitors as potential anticancer drug candidates.
Read More
Cancer

Antisense therapy found to reverse epigenetic changes in glioma models

April 14, 2023
By Coia Dulsat
Researchers at Cold Spring Harbor Laboratory have successfully reversed epigenetic changes and slowed tumor growth in mouse models of diffuse intrinsic pontine glioma (DIPG) using antisense oligonucleotide (ASO) technology. DIPG is a rare pediatric brain cancer where the tumor’s location in the pons of the brainstem makes surgery impossible, and fractioned radiotherapy and chemotherapy efforts have failed to improve survival so far.
Read More
Cancer

Boundless Bio patents ribonucleoside-diphosphate reductase inhibitors for cancer

April 13, 2023
Boundless Bio Inc. has patented ribonucleoside-diphosphate reductase (RNR) inhibitors for the treatment of cancer.
Read More
Cancer cells under magnifying glass
Cancer

DAXX promotes tumorigenesis through de novo lipogenesis, study reveals

April 13, 2023
Tumor cells are known to produce high amounts of intracellular lipids, leading to increased levels of fatty acids, cholesterol and membrane phospholipids. Death domain-associated protein (DAXX) is a small ubiquitin-related modifier (SUMO)-binding protein that plays a role in transcription regulation by interacting with transcription factors such as p53 and NF-κB.
Read More
Cancer

Novel cannabinoid derivatives against pancreatic cancer disclosed

April 13, 2023
Pancreatic cancer is the third leading cause of cancer-related deaths with a 5-year survival rate of 11.5%. The toxicity and chemoresistance to...
Read More
Cancer

Fusion Pharmaceuticals and Astrazeneca’s FPI-2068 cleared to enter clinic in US

April 13, 2023
Fusion Pharmaceuticals Inc. has announced the clearance of IND applications for [225Ac]-FPI-2068 (FPI-2068) and corresponding imaging analogue...
Read More
Previous 1 2 … 500 501 502 503 504 505 506 507 508 … 3710 3711 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 26, 2026.
  • Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

    ENCALS 2026: From genetics to advancing strategies against ALS

    BioWorld Science
    Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
  • Subsense BCI platform

    Next wave of BCI firms builds on pioneers to tackle challenges

    BioWorld
    With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
  • Boehringer Ingelheim identifies new mGlu3 receptor agonists

    BioWorld Science
    Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
  • GT-02897 exerts efficacy in preclinical multiple myeloma

    BioWorld Science
    Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing